Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.
about
CIViC databaseThe emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia.Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape.Two-step ATP-driven opening of cohesin headThe mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study.Molecular Genetic Characterization of Individual Cancer Cells Isolated via Single-Cell PrintingDiagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Isocitrate dehydrogenase mutations in myeloid malignancies.A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice.Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemiaRNA-Guided CRISPR-Cas9 System-Mediated Engineering of Acute Myeloid Leukemia Mutations.The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia.Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.Diagnostic work-up of acute myeloid leukemia.Biological and clinical consequences of NPM1 mutations in AML.Splicing factor mutations in MDS RARS and MDS/MPN-RS-T.Acute myeloid leukemia with del(9q) is characterized by frequent mutations of NPM1, DNMT3A, WT1 and low expression of TLE4.Gene mutational pattern and expression level in 560 acute myeloid leukemia patients and their clinical relevance.Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia.Glioblastoma and acute myeloid leukemia: malignancies with striking similarities.Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations.Methods of Detection of Measurable Residual Disease in AML.Targeted next-generation sequencing using a multigene panel in myeloid neoplasms: Implementation in clinical diagnostics.Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine.Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1.Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.Molecular Pathways: Understanding and Targeting Mutant Spliceosomal Proteins.Precision therapy for acute myeloid leukemia.Potential for subsets of wt-NPM1 primary AML blasts to respond to retinoic acid treatment.Re-emergence of acute myeloid leukemia in donor cells following allogeneic transplantation in a family with a germline DDX41 mutation.Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia.Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies.Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.Validation of a clinical assay of multi-locus DNA methylation for prognosis of newly diagnosed AML.Clonal heterogeneity of -ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemiaEpigenetic-Transcriptional Regulation of Fatty Acid Metabolism and Its Alterations in LeukaemiaGermline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomesGenetic heterogeneity of cytogenetically normal AML with mutations ofEfficient identification of somatic mutations in acute myeloid leukaemia using whole exome sequencing of fingernail derived DNA as germline control
P2860
Q27612411-A908E470-D721-4314-849D-E5F0A991DE23Q30252512-1A4C4148-8E1F-4833-920E-98E7B65E72B6Q30313288-8C2BFF96-794B-4E4D-BDA7-C18D22FB1C5CQ30855484-D36D3212-19D0-42C6-82F5-22B2034B8669Q33437313-A3141DEE-D1A6-47AB-AA8E-FAECD7755CECQ36141141-D28ABA2E-6021-4277-B347-D02BB52C4ED1Q37624593-5B90B4D7-4BD6-4832-BABE-D15B25F9C00FQ37625630-EBB83BEB-1767-4463-83A8-17285AAB2B62Q37648114-51FCDF29-E87C-46C2-9C34-819872B737BDQ38377189-A255FF4F-9A8C-4708-8F04-861F413DDEFEQ38742015-B8C09796-B6BF-40DC-A2A3-B5B5B2C137C4Q38892311-4DA279DA-BAF9-4CEE-BA91-F8BE4C467492Q38904250-7DDBBA34-5312-4B3C-9AE9-6E8807554A54Q39076258-DB1A5CA2-C5D7-4085-8CB9-DA8DED9367A4Q39098284-88366555-F966-4034-A854-702A4F50F4FCQ39279998-B16D02B3-0262-4891-960C-10F58F77B9F8Q40519126-48519B89-D27B-4C22-B433-7EC38B39FD0DQ41498838-F92BF2ED-87DB-4E8E-8CC2-792880235D5FQ44176860-F99C8CD2-755B-4411-9FA0-A59BB61FDF89Q47307310-10C47ED9-4D32-40B4-90C2-14B4263130DFQ47339574-E7B9184A-DBF4-4E1D-B841-7D29025A8833Q47439297-2AFFFBD5-8EF1-47BF-8DB4-A545F74C487CQ47862030-D55BDA60-9BD3-4B03-AFC7-7185EBB5C1BFQ48102067-566E3C60-74F3-440A-B40E-2FE4FAD4D264Q48253128-F8B0D736-5CEB-42DE-A1C4-5CD7F95355F7Q48267407-B9734680-AFD8-4401-815E-9BB6E46A9EB9Q48568744-DD0A0A52-6E16-4F85-B12C-438E86669C32Q49363972-CB38378C-5817-4EE8-96EB-935AF98DDBB7Q49534332-DE9BEE87-74F2-47D6-B3AD-36D9FB44F075Q50097999-7F6071B1-FABA-41A7-BCA8-BFF675D813AAQ51354954-044204C7-D9A7-4121-B439-A4AD908F739AQ51426321-1BA37619-DFC3-436D-8A36-411021A32DF1Q52347210-AC5FD791-C2DC-4E60-AD1C-FB92343FB7FCQ52689074-543D9655-14C4-4A28-9C36-8A57C7D552D0Q55074434-F05176E7-88D3-4936-B62E-F3B797864ED2Q56968572-AEF85EE3-1E72-44FA-B46D-974833AD1E29Q57492375-BC33F7AA-F448-4CB7-979F-BF510A8B0B1CQ57734029-D9831E66-0114-41B7-BD46-45CFEA52BACEQ57795864-08A4DB8B-92D0-45DD-8EDA-9B1ED7D6D3B9Q58743748-735AE63D-2F9B-441E-83EC-F90BECCA1D35
P2860
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.
description
2016 nî lūn-bûn
@nan
2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.
@ast
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.
@en
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.
@nl
type
label
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.
@ast
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.
@en
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.
@nl
prefLabel
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.
@ast
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.
@en
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.
@nl
P2093
P50
P1433
P1476
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia
@en
P2093
AMLCG Study Group
Andreas Faldum
Annika Dufour
Bernhard Wörmann
Bianka Ksienzyk
Evelyn Zellmeier
Jan Braess
Kathrin Bräundl
Luise Hartmann
Maja Rothenberg-Thurley
P304
P356
10.1182/BLOOD-2016-01-693879
P407
P577
2016-06-10T00:00:00Z